Group items tagged

Duncan Rudkin, the CEO of the General Pharmaceutical Council (GPhc) has highlighted the importance of strengthening pharmacy governance to provide clarity around how pharmacies are organised and managed. This will ensure that patients and the public continue to receive safe and effective pharmacy care, he said while speaking at the annual Sigma Conference in London on Sunday (5 November). According to him, there could be rules that outlined the essential roles and responsibilities of responsible pharmacists, and professional standards for responsible pharmacists, superintended pharmacists and chief pharmacists. He also announced that the GPhC will be shortly launching a consultation to integrate a new set of standards for the statutory role of hospital chief pharmacists "which up until recently has never been recognised in law." It is expected to be launched by early January 2024. However, Duncan, emphasised that they cannot start the work on standards for responsible and superintendent pharmacists until they know the government plans in relation to supervision. "Because of course, the responsible pharmacists' regime, and the supervision regime are in many ways intertwined, and can't certainly be looked at separately.

In 2024, cannabis users will get more protection from their employers when it comes to smoking outside of work. In the meantime, here's a refresher on who can use weed - and when and where - in California. Can my employer penalize me for cannabis use? California recently passed a new cannabis bill, protecting employees from weed bias, but it will be a while before it goes into effect. Called AB 2188, it bans employers from discriminating against employees based on their use of weed off the job and away from the workplace. This includes the hiring, employment and termination processes. The law's exceptions include people working in the construction and building industry or positions that require federal background clearances. And while it protects off-duty smoking, employers will still have the right to fire or suspend employees for using weed or being high while at work. Although the bill was signed by Gov. Gavin Newsom in September, it won't be carried out until January 2024. Weed might be legal, but not for everyone Recreational cannabis use has been legal since 2016, but only for those 21 years old and over. Those under 18 who are caught with weed will be subject to drug education or counseling and community service. People who are older than 18 but under 21, will be fined up to $100. But minors can apply for a medical marijuana identification card to get weed for medicinal purposes. In California, children under 18 years old can apply as a patient if they are emancipated or have declared self-sufficiency status, according to the state's Department of Health. If they do not have this status, then the county will contact the individual's parent or legal guardian. The legal limit of weed How much cannabis you can have on hand is limited in California, according to the state's health and safety code. You'll be penalized if you possess more than 28.5 grams of weed, or more than eight grams of concentrated cannabis - essentially about one

More than 1.5 million courses of Pfizer's COVID-19 antiviral drug Paxlovid have expired unused in European countries by the end of November, the health analytics firm Airfinty has revealed. It is predicted that the figure could surge to 3.1 million, at a value of $2.2 billion (around £1.73 billion), by the end of Feb 2024. According to Airfinty analysis, Britain has the highest unused stock, with an estimated one million expired drug courses worth $700 million (over £550 million). With 2.2 million courses estimated to expire unused by the end of June 2024 due to the low prescription of the antiviral in the country, the total drug value wasted in the UK could reach $1.5 billion (£1.1 billion), the report added.

Hospitals and healthcare providers across the UK have been notified about the shortage of an anti-inflammatory medicine caused by a manufacturing failure. The Department of Health and Social Care (DHSC) on Friday (3 May) issued a National Patient Safety Alert stating that Erelzi 50mg solution for injection in pre-filled pen will be out of stock from early May until mid-July 2024. "The supply issues have been caused by a manufacturing failure resulting in delays in production and the implementation of global allocations," it said. However, it noted that homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to supply existing patients until mid/late May 2024. Although Erelzi 50mg pre-filled syringes (PFS) are still available, they cannot support a full increase in demand, the DHSC warned.

A report released by Community Pharmacy England (CPE) has warned that pharmacies across England are grappling with daily medicine supply challenges, posing significant risks to patients' health. The Pharmacy Pressures Survey 2024: Medicines Supply Report, which is based on the views of the owners of over 6,100 pharmacy premises in England and 2,000 pharmacy team members, has exposed some alarming trends concerning medicine supply problems in the country. Almost all pharmacy team members surveyed (97 per cent) reported patients being inconvenienced due to medicine supply issues, and 79 per cent of the participants said that the worsening situation is putting patient health at risk. Nearly all respondents reported patient frustration stemming from medicine supply issues, with 84 per cent of them saying they had experienced aggression from patients. Additionally, 98 per cent indicated an increase in 'owings,' where patients receive only part of their prescription and must return to the pharmacy for the remaining medication(s) at a later time."

PAFP Spring Family Medicine Essentials Summit is organized by the Pennsylvania Academy of Family Physicians and will be held from Apr 05 - 06, 2024.

Register for upcoming Obstetrics and Gynecology Conferences, Online CME Courses, Live Webinars, In-person Medical Conferences & Hybrid Events in 2024. Discover the future of Obstetrics and Gynecology with a wide array of well-curated CME and CE conferences, all in one place here at eMedEvents.

Register for upcoming Emergency Medicine Conferences, Online CME Courses, Live Webinars, In-person Medical Conferences & Hybrid Events in 2024. Explore all the Emergency Medicine CME/CE conferences and online courses hosted by renowned medical experts and institutions.

A full CPE Committee Meeting was organised in London on April 17 and 18, 2024, to discuss crucial sectoral issues. Key topics discussed during the two-day meeting included intolerable pressures on pharmacy owners, the ongoing Community Pharmacy Contractual Framework (CPCF) negotiations, implementation of the Pharmacy First service, and governance changes. Committee Members reviewed the progress of CPCF negotiations with the Department of Health and Social Care (DHSC) and NHS England. These critical negotiations are being led by the Negotiating Team (NT), which includes independent pharmacy owners and representatives of CCA and non-CCA multiples. The CPE has been advocating for an uplift to the core global sum, margin write-offs, an agreed mechanism for regular funding increases linked to activity and inflation, annual uplifts to service fees, more fundamental reform of the margin delivery framework and an economic review of the medicines supply chain. The Committee also discussed the results of the 2024 Pharmacy Pressures Survey, which was conducted during March and April.

Despite the challenges confronting pharmacy owners and their teams today, many in the industry hold the belief that the future for community pharmacy is promising. In a poll conducted at the beginning of the Pharmacy Business Conference 2024, 58 per cent of participants agreed that the future of community pharmacy is positive, with 13 per cent expressing strong agreement. However, 27 per cent expressed disagreement, with 3 per cent strongly disagreeing that the sector's future is optimistic. By the end of the conference, a higher percentage of individuals (67 per cent) showed a positive outlook for community pharmacy, with over half indicating strong agreement with its positivity. The number of participants who disagreed with it decreased to 11 percent.

Opella Healthcare, trading as Sanofi Consumer Healthcare, recently signed a dual partnership agreement with Alliance Healthcare and Phoenix Healthcare Distribution for the wholesale supply of its consumer healthcare products to community pharmacies throughout the United Kingdom. The new dual pharmacy wholesale partnership model, which became effective on 1 February 2024, underscores Sanofi's commitment to delivering exceptional customer service to its customers, the company said in a press release. The groundbreaking collaboration is expected to enhance operational efficiency as part of the company's go-to-market model, facilitating improved service levels and stock availability of key products, including Cialis® Together, Allevia®, Buscopan®, Dulcolax®, and Phenergan, to community pharmacies in the UK. Nick Linton, head of UK country operations, Sanofi Consumer Healthcare, said that the company is committed to supporting the "self-care agenda" in the UK. "Making healthcare as simple as it should be to bring health and wellbeing to all is a key priority for us in 2024 and beyond," he commented.

All 42 integrated care boards (ICBs) in England have signed memorandums of understanding for the NHS Independent Prescribing Pathfinder programme, the first nationally-funded prescribing service in the country. Anne Joshua, interim deputy director of pharmacy commissioning at NHS England, made the revelation during the 'Chief pharmaceutical officer bi-monthly webinar' held on 7 March 2024, as reported by The Pharmaceutical Journal. In the initial phase of the programme, 210 community pharmacies across all ICBs will trial independent prescribing, ahead of establishing a commissioning framework for the service. Giving an update on the pathfinder programme, Joshua confirmed that 164 of these potential pathfinder sites had registered for the programme as of 29 February 2024. Additionally, she announced the clinical models to be followed by the participating pharmacies and presented a graph showing an overview of the services they will provide.

Community Pharmacy England (CPE) has released a series of resources to help pharmacy owners and their teams promote the new Pharmacy First service, which is slated for launch on 31st January 2024. Pharmacists can use a variety of resources, including posters, social media content, flyers and a local press release, to raise awareness of the new service to patients and members of the public. The promotional materials are now available to download from the Committee's website. "The messaging and graphics have been developed with the input of pharmacists and pharmacy owners, to highlight the benefits of the service to patients, the public, and the NHS," it said. CPE has been providing a range of information, guidance and resources to support community pharmacies in the implementation of the new service. Beginning Monday 29 January 2024, the committee will be hosting a series of online drop-in sessions (no need to register) to assist pharmacy professionals with any queries they may have on the service.

PAFP Spring Family Medicine Essentials Summit is organized by the Pennsylvania Academy of Family Physicians and will be held from Apr 05 - 06, 2024. Spring Family Medicine Essentials CME Summit - 7+ patient safety credits, including state-mandated opioid and child abuse

Register for upcoming Nursing Conferences, Online CME Courses, Live Webinars, In-person Medical Conferences & Hybrid Events in 2024.

Pharmacy owners discussed the key concerns and priorities for the future at the Community Pharmacy England's (CPE) digital briefing event held last week (on 7 May 2024). More than 500 pharmacy owners and their representatives registered for the event, which provided them an opportunity to learn more about the committee's work in key areas and share their views on important issues. Major concerns raised by them included underfunding, dispensing at a loss, and challenges in implementing Pharmacy First. Attendees described the new service as "slow", "challenging" and "underfunded", while also highlighting the importance of improving GPs' understanding of the service.

The cannabis market is growing day by day. In North America, it's expected to reach about $47.3 by 2024. Learn more now.

The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI). Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS). "We are deeply concerned by this decision. It has left us no choice but to take legal action." "While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028." "The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS. The association had raised its full participation in the negotiations with the Government last November.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes on Tuesday (27 June). "There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM)," said DHSC. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to normal until at least mid-2024. Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative treatment options.

Starting from January 2024, it will be compulsory for medicine suppliers in the NHS supply chain in England to submit an Evergreen Sustainable Supplier Assessment each year. Suppliers who fail to submit the sustainability assessment will not be placed on medicines contracts, said NHS England. The NHS has taken this move as part of its ambition to reach carbon net zero by 2045. The Evergreen Sustainable Supplier Assessment is a self-assessment and reporting tool for suppliers to share sustainability information with the NHS. Chris McAleer, medicines net zero project delivery manager at NHS England, announced this new rule at the Guild of Healthcare Pharmacists' Procurement and Distribution Interest Group Autumn Symposium held in Birmingham on 2 November 2023.